Beijing’s response to U.S. requests in the course of a long campaign to stem the flow of fentanyl from labs in China to the cities and towns of America, where overdose deaths from opioids and other drugs now exceed 100,000 per year, has proven inadequate as the drug supply chain adapts to find new outlets. Thwarting the illegal fentanyl trade calls for new approaches that continue to push for China’s cooperation while strongly emphasizing self-regulation and best practices in the global pharmaceutical industry. That’s according to a panel of experts on China and the illegal drug trade who presented their views in a Brookings Institution virtual event on March 28. The panelists were Vanda Felbab-Brown, author of a recent report on China’s role in the fentanyl trade; Rupert Stone, an Istanbul-based journalist; and Ryan Hass, a Brookings senior fellow and former foreign service officer in the Obama administration with a …